StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Amit Seth

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byAmit SethHorizon: NA (inferred Swing (≤2wk))29 Sept 2026via CNBC Awaaz.

Entry₹2,391Inferred
Target₹2,450
Total upside +2.47% (call closed)
Stop loss₹2,340-2.13% risk
Exit₹2,34030 Sept 2026, 3:00 pm
Stop-loss hit-2.13%
Follow Amit Seth for new calls(30% target hit, 193 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 2 active Swing calls on GLENMARKSee 282 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 30 Sept 2026
6 supporting1 neutral0 opposing
Supports the BUY call (6)

Glenmark Pharma gets EIR for Goa facility from US FDA

NewsGoogle News·23 Sept · 6d ago

(opens in new tab)

Glenmark Receives US FDA Inspection Report For Goa Facility; Shares Rise 0.28%

NewsGoogle News·23 Sept · 1w ago

(opens in new tab)

Glenmark Pharmaceuticals' Goa facility received an Establishment Inspection Report (EIS) from the U.S. FDA with a Voluntary Action Indicated (VAI) classification, suggesting no major compliance issues

BSE · Company Update·23 Sept · 1w ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·23 Sept · 1w ago

Glenmark Pharmaceuticals Ltd spurts 0.5%, gains for fifth straight session

NewsGoogle News·22 Sept · 1w ago

(opens in new tab)
Neutral / worth noting (1)

Glenmark Pharmaceuticals (NSE: GLENMARK) U.S. FDA Compliance Update for Goa Facility

NewsGoogle News·23 Sept · 6d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Amit Seth

Every call and its outcome